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Abstract
Background: To evaluate the cost-effectiveness of the first nationwide delivery of long-lasting
insecticide-treated nets (LLITNs) as part of the 2004 measles vaccination campaign in Togo to all
children between nine months and five years.
Methods: An incremental approach was used to calculate the economic costs and effects from a
provider perspective. Effectiveness was estimated in terms of malaria cases averted, deaths averted
and Disability-Adjusted Life Years (DALYs) averted. Malaria cases were modelled using regional
estimates. Programme and treatment costs were derived through reviews of financial records and
interviews with key stakeholders. Uncertain variables were subjected to a univariate sensitivity
analysis.
Results: Assuming equal attribution of shared costs between the LLITN distribution and the
measles vaccination, the net costs per LLITN distributed were 4.41 USD when saved treatment
costs were taken into account. Assuming a constant utilization of LLITNs by the target group over
three years, 1.2 million cases could be prevented at a net cost per case averted of 3.26 USD. The
net costs were 635 USD per death averted and 16.39 USD per DALY averted, respectively.
Conclusion: The costs per case, death and DALY averted are well within commonly agreed
benchmarks set by other malaria prevention studies. Varying transmission levels are shown to have
a significant impact on cost-effectiveness ratios. Results also suggest that substantial efficiency gains
may be derived from the joint delivery of vaccination campaigns and malaria interventions.
Background
Evidence on the effectiveness of insecticide-treated nets
(ITNs) to prevent malaria in endemic regions is well
established [1-5]. The cost-effectiveness of ITNs has also
been widely reported particularly in the context of rand-
omized control trials [6-8]. However, despite these posi-
tive results, mechanisms for public sector distribution of
bed nets have struggled to match the coverage levels of
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vaccination campaigns [9]. The challenge remains in dem-
onstrating the cost-effectiveness of delivering ITNs in non-
trial settings at a regional or national level.
Recent studies indicate that vaccination campaigns have
achieved high levels of coverage, especially if they are a
one-off vaccination, such as the measles vaccine [10,11].
This has prompted campaigns, which distribute ITNs in
combination with vaccinations, in an attempt to improve
the coverage rates of ITNs, while minimizing any duplica-
tion of delivery costs across the two interventions. The
results of trials at the sub-national level have been encour-
aging with household ownership of ITNs reaching levels
of above 90% in Ghana and usage rates of 68% in Ghana
and up to 77% in urban Zambia [12,13].
The Togo Integrated Child Health Campaign represents
the first campaign on a national scale, in which various
health interventions, including the distribution of a long-
lasting insecticide-treated bed net (LLITN) and measles
vaccination were jointly delivered to each household with
at least one eligible child aged nine to 59 months [14-16].
Not all components of the campaign were delivered
simultaneously; therefore this cost-effectiveness analysis
(CEA) concentrates on the malaria and measles compo-
nents of the campaign which were jointly implemented in
December 2004. This study makes two important contri-
butions to current knowledge in this area. This is the first
economic evaluation of LLITN-distribution as part of an
integrated health campaign. It provides an important
opportunity to compare these results with other delivery
mechanisms that have been applied at the national level
such as the social marketing of bed nets [7]. Secondly, this
study reveals that substantial costs are shared by the
malaria and measles components of the campaign, high-
lighting the potential economies of scope inherent in the
joint nature of the campaign.
Methods
An incremental approach was used to estimate costs and
effects. This involved comparing the campaign to a sce-
nario of no public sector ITN distribution ('do-nothing'
approach). Findings are presented from a provider per-
spective; only the costs and effects borne by the ministry
of health and donors are considered. All relevant stake-
holders were interviewed and asked to disclose their con-
tribution to the campaign. Economic costs (reflecting full
opportunity costs of resource use [17]) are divided into
capital and recurrent costs and estimated using the ingre-
dients approach in which all provider resources required
in the delivery of the campaign are valued [18]. The main
recurrent costs included personnel, overheads (such as
office space, support staff, utilities, etc.) and transport.
Overheads were apportioned according to the number
and time of personnel dedicated to the campaign against
total number of personnel. Capital costs (equipment,
vehicles and buildings) were annualized over their esti-
mated lifetime at a discount rate of 5% (Central Bank of
West African States, BCEAO, personal communication).
All other costs occurred during a period of less than one
year and were therefore not discounted. Shared costs were
apportioned equally between the malaria and measles
components in the base case calculation. Costs were con-
verted into US Dollars (USD) at the official exchange rate
of 1 December 2004 when all major expenses were
incurred (1 USD = 493 Franc CFA, Oanda Corporation).
Two sets of cost-effectiveness ratios were calculated. The
first is based on gross estimates that do not take into
account potential resource savings and the second set did
(i.e. net cost-effectiveness ratios). Resource savings were
derived by multiplying the average outpatient treatment
costs for a child with malaria by the number of cases
averted. This estimate was then adjusted for the percent-
age of children under the age of 5 that access a public
health facility in the event of febrile illness in Togo (30%
following a recent evaluation by the Malaria Control Pro-
gramme of the Ministry of Health [19]).
To determine treatment costs, a facility survey was con-
ducted in July 2005 in joint collaboration with the Togo-
lese Ministry of Health (MoH). A total of 31 public,
private-for-profit and private-not-for-profit facilities were
surveyed in urban (20) and rural (11) areas and across all
levels of care (three University Hospitals, seven Regional
Hospitals, six District Hospitals and 15 peripheral health
centres). Representatives from each facility were inter-
viewed by other health care professionals (hired by the
MOH) about staff time, equipment and consumables
used to treat a typical malaria case as well as the overhead
costs of the facility or department. Only outpatient costs
were considered in this analysis in the absence of informa-
tion on the proportion of inpatient vs. outpatient cases.
Health effects were measured in terms of cases of malaria
averted, deaths averted and DALYs averted. The usage of
LLITNs shortly after the campaign was 54% [20]. In the
absence of information on LLITN utilization rates over
time and on the duration of usage, a constant usage of
LLITNs at 54% for three years by children under-five years
of age was assumed. This assumption was adopted since
the first two coverage surveys indicated that ownership of
LLITNs had only marginally fallen nine months post-cam-
paign [20]. Physical durability of LLITNs is dependent on
the local context (number of washings, handling of nets),
but recent experiences indicate that LLITNs of the kind
used in Togo may last three years and longer (Gimnig,
personal communication).Malaria Journal 2008, 7:73 http://www.malariajournal.com/content/7/1/73
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To calculate the number of deaths averted by the cam-
paign, a reduction of all-cause mortality of 17% among
one to 59 month-old children was applied as described in
a Cochrane Review by Lengeler [3]. A figure of 182,000
live births per year in Togo as reported for the year 2004
[21] was used. From the overall under-five mortality of
140 per 1,000 live births per year the neonatal mortality
rate (40/1,000 live births) was subtracted to obtain the
mortality among one to 59-month old children [22-24].
Because the reduction in mortality described in the
Cochrane Review was based on a higher utilization rate
(70%), adjustments were made for the lower level of uti-
lization in Togo. The impact of utilization rates on overall
findings was tested in the sensitivity analysis.
In the absence of published morbidity and mortality data
for children in Togo, recent estimates by the Child Health
Epidemiology Reference Group (CHERG) were applied.
These assume a median incidence of 1,209 malaria cases
per year per 1,000 <5 children in middle Africa (including
Togo) [25]. This was varied in the sensitivity analysis to a
high transmission scenario reported from neighbouring
Ghana (1,727 per 1,000) [26] and a low transmission sce-
nario from neighbouring Benin (237 per 1,000) [27].
The number of DALYs averted was based on the estimated
ratios of episodes, anaemia cases, neurological sequelae
and deaths resulting from malaria cases as estimated by
the CHERG [25]. Disability weights identified by the Glo-
bal Burden of Disease Project were used; 0.211, 0.012 and
0.471 for malaria episodes, anaemia and neurological
sequelae, respectively [28]. Life tables for the year 2000 for
Togo indicated a life expectancy of 51.75 and 56.2 years
for 0–1, and 1–5 year old children, respectively [29]. The
duration of illness has been applied differently across
studies [30]: in this study a duration of two weeks per
malaria episode was assumed, eight weeks per anaemia
case and an average of 35.4 years for treated and untreated
neurological sequelae. DALYs were discounted at 3%
without an age weighting correction as no consensus on
its use has yet been demonstrated [30]. The impact of
including an age weighting correction was tested in the
sensitivity analysis.
It was also the intention of this study to examine the
extent to which varying the attribution of shared costs
between the malaria and measles components of the cam-
paign influenced cost-effectiveness. In the main analysis,
shared costs were attributed equally while in the sensitiv-
ity analysis all shared costs were allocated to measles or to
malaria. Other uncertain variables subjected to a univari-
ate sensitivity analysis included discount and exchange
rates, lifetime of vehicles, price of LLITN, duration of
LLITN usage, utilization rate of LLITNs, malaria transmis-
sion levels and the percentage of children with febrile ill-
ness accessing public health facilities. The study was part
of a larger evaluation which gained ethical approval from
the Togolese Ministry of Health and CDC, Atlanta.
Results
Table 1 reveals that the gross economic cost of the Inte-
grated Child Health Campaign (malaria and measles
components) was 6.4 million USD. Capital expenditure
(including the acquisition of LLITNs) accounted for 4.1
million USD and recurrent expenditure accounted for 2.3
million. More than half of total expenditure was attrib-
uted to the purchase of LLITNs (60.8%). Approximately
4.9 million USD, or 75.2% of total campaign costs, repre-
sents costs specific to the malaria component. Shared
expenditure (i.e. expenditure that could not be attributed
specifically to the malaria or measles component)
accounted for 1.1 million USD or 16.4% of total costs.
Shared costs mainly consist of salaries of personnel, their
respective office space and overheads.
Table 2 summarizes the costs, effects and cost-effective-
ness ratios for the intervention. Assuming that shared
costs are split equally between the malaria and measles
components (i.e. 50% each to the malaria and the measles
component of the campaign), the gross costs of the
malaria component alone were calculated at 5.38 million
USD. With 1.2 million malaria cases averted over three
years at a treatment cost per outpatient case of 3.79 USD,
treatment costs averted amounted to 1.39 million USD.
By subtracting these resource savings from total malaria
programme costs, total net costs were 3.99 million USD
for the malaria component of the campaign.
According to the MoH, a total of 907,500 LLITNs were dis-
tributed during the campaign [14]. This results in a gross
Table 1: Total campaign expenditure








Room rental 110,895 1.7
Overheads 59,254 0.9
Fees (customs, bank charges etc.) 27,539 0.4




TOTAL 6,448,695 100.0Malaria Journal 2008, 7:73 http://www.malariajournal.com/content/7/1/73
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cost of 5.95 USD and net cost of 4.41 USD per LLITN dis-
tributed, if shared costs are attributed equally.
It is estimated that 6,285 deaths and 1.2 million cases are
averted between the ages of 9–59 months over a period of
three years. The gross cost of the malaria component of
the campaign equals 856 USD per death averted and 4.40
USD per case averted. The equivalent net costs were 635
USD per death averted and 3.26 USD per case averted.
Based on the assumption of constant usage of LLITN over
three years, the total number of DALYs averted due to the
malaria component of the campaign was 243,472. The
largest share of malaria attributable DALYs is associated
with discounted years of life lost (YLL) due to malaria;
these amount to 189,249. The gross cost per DALY averted
is calculated at 22.10 USD; the equivalent net cost is 16.39
USD.
Table 3 illustrates the results of the sensitivity analysis.
One of the major assumptions underlying this evaluation
concerns the attribution of shared costs: For the main
analysis shared costs were attributed equally to the
malaria and measles components of the campaign, which
resulted in 16% of total programme costs allocated to
measles and 83% to malaria. Attributing all shared costs
to the malaria component (supposing that this compo-
nent would have been implemented separately) would
account for nearly 5.9 million USD for the malaria com-
ponent or 92% of the total campaign expenditure. Alter-
natively, if all shared costs were attributed to measles, the
revised malaria costs would be 1.6 million USD or 25% of
total campaign costs. The gross and net cost per DALY
averted would change from 22.10 and 16.39 USD to
24.28 and 18.56 USD, respectively, if all shared costs were
absorbed by the malaria component or to 19.93 and
14.21 USD, respectively, if all shared costs were borne by
the measles component.
Changing the average duration of usage of an LLITN from
three to two years increases the gross and net cost per
DALY averted from 22.10 and 16.39 USD to 33.15 and
27.44 USD, respectively. The equivalent figures for four
year usage are gross costs of 16.58 USD and net costs of
10.86 USD. Altering the usage for <5 year old children
from 54% in Togo [20] to 70% as applied in the Cochrane
review [3], results in decreases in gross cost per DALY from
22.10 to 20.72 USD and net cost per DALY from 16.39 to
13.76 USD.
The impact of changing incidence rates was also investi-
gated by applying a high transmission scenario from
Ghana (incidence of 1,727 per 1,000 per year [26]) and a
low transmission scenario from Benin (incidence of 237
per 1,000 per year [27]). See Table 3 for the impact on the
cost per case averted. Because these case studies did not
describe the incidence of anaemia and neurological
sequelae, the number of DALYs averted in these scenarios
could not be calculated.
The number of children accessing public health facilities
for the treatment of febrile illness varies significantly
across sub-Saharan Africa. The current estimate for Togo is
30% [19]. Reducing this to 10% changes the net cost per
DALY averted from 16.39 to 20.20 USD. An increase from
30% to 100% reduces the net cost per DALY averted from
16.39 to 3.05 USD.
Changing the discount rate, exchange rate, price of LLITN
or lifetime of vehicles does not have a significant impact
on campaign costs or cost-effectiveness ratios (Table 3).
Including an age-weighting in the DALY calculations also
had little impact with the gross and net costs per DALY
averted changing from 22.10 and 16.39 USD to 22.17 and
16.44 USD, respectively.
Discussion
This study estimates the cost-effectiveness of delivering
LLITNs as part of a nationwide health campaign. In sum-
mary, we calculate gross and net costs of 4.40 and 3.26
USD per case of malaria averted; 856 and 635 USD per
death averted; and 22.10 and 16.39 USD per DALY
averted. The sensitivity analysis demonstrated that the
results are robust to moderate changes in exchange and
discount rates as well as changes in the price of LLITNs.
Changes in the lifetime and/or usage rates of LLITNs as
well as the rate of children with febrile illness accessing
public health facilities had a greater influence over cost-
effectiveness estimates.
Table 2: Cost-effectiveness of the malaria component of the 
Togo Integrated Child Health Campaign
Costs and savings
Total cost of malaria component 5.38 million USD
Total saved treatment costs 1.39 million USD
Net costs of the malaria component 3.99 million USD
Effectiveness
Number of LLITNs distributed 904,500
Number of cases averted 1,223,862
Number of deaths averted 6,285
Number of DALYs averted 243,472
Gross cost-effectiveness
Gross cost per LLITN distributed 5.95 USD
Gross cost per case averted 4.40 USD
Gross cost per death averted 856 USD
Gross cost per DALY averted 22.10 USD
Net cost-effectiveness
Net cost per LLITN distributed 4.41 USD
Net cost per case averted 3.26 USD
Net cost per death averted 635 USD
Net Cost per DALY averted 16.39 USDMalaria Journal 2008, 7:73 http://www.malariajournal.com/content/7/1/73
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Overall, the cost effectiveness of the campaign approach
to deliver LLITNs in Togo compares favourably against
other public sector ITN programmes. For example, in
Ghana, the provision of ITNs and re-treatment was
reported to cost 2,112 USD per death averted or 77 USD
per DALY averted [31]. In Kenya, the cost per death
averted through ITN distribution was estimated at 2,958
USD [32]. A modelling exercise undertaken by Goodman
and colleagues reported costs of between 19 and 85 USD
per DALY averted (1999 prices) for the distribution and
re-treatment of ITNs across Sub-Saharan Africa [33,34].
More recently, the Disease Control Priorities Project
(DCPP) found the cost per DALY averted fell between 11
and 17 USD depending on the frequency of re-treatment
and insecticide used for re-treatment of conventional ITNs
[35].
The Togo results can also be compared against other
methods for distributing bed nets. For example, a recent
cost-effectiveness analysis (2003) of social marketing of
ITNs in two rural districts of Tanzania estimated that it
cost 1,560 USD per death averted, 57 USD per DALY
averted and 8.30 USD per net distributed [36]. Perhaps
more relevant are the results from one of the few social
marketing studies of LLITNs conducted at the national
level. The study from Malawi (2005) which distributed
almost 1.5 million conventional ITNs, estimated that it
cost 2.49 USD to distribute each net [7] compared to 5.95
USD under the Togo study where approximately 907,000
nets were distributed. Further comparisons can be made
between this study and other malaria control mechanisms
such as indoor-residual spraying (IRS) which has been
estimated to cost between 16 and 58 USD per DALY
averted [32,33] and most recently, between 5 and 34 USD
[35]. Chemoprophylaxis for children can cost anywhere
between 3 and 41 USD per DALY averted and intermittent
presumptive treatment of pregnant mothers (IPTp)
between 4 and 29 USD per DALY averted [32,33]. Esti-
mates from this study lie within the cost per DALY range
for both IRS and IPT. The results from this study also fall
below the benchmark of 30 USD per DALY for highly
Table 3: Sensitivity Analysis – Impact of varying major assumptions on gross and net costs per malaria case averted
Variable Change Impact on gross cost per 
malaria case averted
Impact on net cost/savings per 
malaria case averted
Attribution of shared campaign 
costs
All shared costs borne by measles 
component.
Decrease from 4.40 USD to 3.96 
USD.
Decrease from 3.26 USD to 2.83 
USD.
Attribution of shared campaign 
costs
All shared costs borne by malaria 
component.
Increase from 4.40 USD to 4.83 
USD.
Increase from 3.26 USD to 3.69 
USD.
Discount Rate Decrease from 5% to 3% Minimal decrease from 4.40 USD 
to 4.39 USD.
Minimal decrease from 3.26 USD 
to 3.25 USD.
Discount Rate Increase from 5% to 7% Minimal increase from 4.40 USD to 
4.41 USD.
Minimal increase from 3.26 USD to 
3.27 USD.
Lifetime of vehicles From 8 and 10 years (depending on 
model) to 5 years
No change. Minimal increase from 3.26 USD to 
3.27 USD.
Exchange Rate From 1/12/2004 to 1/10/2004 Minimal increase from 4.40 USD to 
4.41 USD.
Minimal increase from 3.26 USD to 
3.28 USD.
Exchange Rate From 1/12/2004 to 1/1/2005 Minimal increase from 4.40 USD to 
4.43 USD.
Minimal increase from 3.26 USD to 
3.30 USD.
Price of LLITN 10% increase Increase from 4.40 USD to 4.72 
USD.
Increase from 3.26 USD to 3.58 
USD.
10% decrease Decrease from 4.40 USD to 4.08 
USD.
Decrease from 3.26 USD to 2.94 
USD.
Duration of usage of LLITN From 3 years to 2 years Increase from 4.40 USD to 6.60 
USD.
Increase from 3.26 USD to 5.46 
USD.
From 3 years to 4 years Decrease from 4.40 USD to 3.30 
USD.
Decrease from 3.26 USD to 2.16 
USD.
Usage of LLITN among < 5 year 
old children
From current ratio of 54% in Togo 
to higher rates used in Cochrane 
review (70%)
Decrease from 4.40 USD to 3.39 
USD.
Decrease from 3.26 USD to 2.25 
USD.
Increase in transmission From incidence of 1,209 per 1,000 
p.a. to 1,727 per 1,000 p.a.
Decrease from 4.40 USD to 3.08 
USD.
Decrease from 3.26 USD to 1.94 
USD.
Decrease in transmission From incidence of 1,209 per 1,000 
p.a. to 237 per 1,000 p.a.
Increase from 4.40 USD to 22.43 
USD.
Increase from 3.26 USD to 21.29 
USD.
Percentage of febrile children 
accessing public health facilities
From 30% to 10% No change by definition. Increase from 3.26 USD to 4.02 
USD.
From 30% to 100% No change by definition. Decrease from 3.26 USD to 0.61 
USD.Malaria Journal 2008, 7:73 http://www.malariajournal.com/content/7/1/73
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cost-effective interventions which was recommended by
the World Health Organization in 1996 [37].
While it can be useful to contextualize cost-effectiveness
estimates in this way, there are some important differ-
ences across studies that can undermine comparability.
For example, most existing studies focus on ITNs (with the
need for periodic re-treatment) as opposed to LLITNs.
There is also considerable variation in the outcome meas-
ures used and the rates of transmission applied. Some
studies acknowledge resource savings while others do not.
'Benchmarks' and 'thresholds' are only a guide to deci-
sion-makers. With most African governments currently
devoting less than 5 USD per person annually to public
health [38] it is difficult to see how a publicly funded bed
net programme could be sustained even if it represented
good value for money as is the case with delivering LLITNs
as part of the Togo health campaign.
A number of methodological issues must also be borne in
mind when interpreting the results of this analysis. Firstly,
in the absence of pre- and post-campaign incidence data
on malaria, all cost-effectiveness estimates are based on
regional averages. While there is no particular reason to
think that Togo is an outlier in this respect, this can only
be confirmed through the collection of primary effective-
ness data. Secondly, estimates are based on the assump-
tion that utilization will be guaranteed at the current rate
(or above) for no less than three years. This assumption
needs to be tested. Thirdly, it is conceivable that addi-
tional resources may be required to maintain current cov-
erage rates of LLITNs and this would increase the overall
cost of this intervention. Fourthly, in the absence of data
on the percentage of hospitalizations attributable to
malaria, resource savings are based on the average cost of
outpatient treatment only. Net costs for Togo are, there-
fore, likely to be conservative since they do not include the
relatively high costs of inpatient care. Finally, cost-effec-
tiveness was assessed from a provider viewpoint. Those
wishing to explore the social desirability of this type of
intervention should consider any additional costs and
benefits to recipients of LLITNs and their families. For
example, the estimates of effectiveness presented here do
not acknowledge the possible effects of LLITNs on family
members sleeping in the same room as an LLITN user.
Savings in treatment costs to households using LLITNs
have also been excluded from this analysis. It is expected
that the inclusion of such benefits will further promote
the cost-effectiveness of LLITN distribution through mass
health campaigns.
Conclusion
On the basis of cost-effectiveness, the results of this anal-
ysis suggest that delivering LLITNs as part of a wider
health campaign compares well with other malaria con-
trol interventions and results are even more favourable if
averted treatment costs are considered. These findings also
suggest that there are potential efficiency gains to be had
by incorporating LLITNs into health campaigns like that
of Togo. The total cost of the Togo campaign was 6.5 mil-
lion USD. Of this amount, 1.1 million USD represents
shared costs between the two components of the cam-
paign. Assuming equal attribution of shared costs, the
gross cost per LLITN distributed was calculated at 5.95
USD. The sensitivity analysis revealed that attributing all
shared costs to the malaria component increases the dis-
tribution costs per LLITN from 1.62 USD to 2.21 USD.
While the true allocation of shared costs can only be deter-
mined through separate costings of the measles and
malaria components of the campaign, this analysis
implies that reductions in average total costs may be
achieved by extending the range of goods delivered in this
type of campaign to include LLITNs.
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